Lightcast Discovery

Lightcast Discovery is a private, pre-revenue platform company pioneering advanced single-cell functional analysis. Its core technology, Envisia, is a droplet-based platform that allows for massively parallel, precise control of single-cell assays, including the study of biomolecule secretion, cell-cell interactions, and targeted cell killing. The company is currently in a limited commercial launch phase for Envisia, targeting researchers in drug discovery and translational research to provide deeper functional insights beyond genomic or transcriptomic data.

Envisia Platform: A droplet microfluidics-based system for massively parallel, single-cell functional analysis. It features precise on-demand droplet merging for cell-cell interaction studies, sequential multi-step assays, and real-time export of live cells based on functional criteria.

Lightcast competes in the single-cell analysis market against giants like 10x Genomics (focused on sequencing) and BD, as well as other droplet/microfluidics companies. Its differentiation lies in its focus on controlled, sequential functional assays and live-cell export, carving out a niche in functional phenotyping versus genomic profiling.